新型药物治疗：它们对骨折预防的作用。

Newer drug treatments: their effects on fracture prevention.

作者信息

Geusens Piet, Reid David

机构信息

Biomedical Research Institute, University Hasselt, Campus Diepenbeek, Belgium.

出版信息

Best Pract Res Clin Rheumatol. 2005 Dec;19(6):983-9. doi: 10.1016/j.berh.2005.07.003.

DOI:10.1016/j.berh.2005.07.003

PMID:16301192

Abstract

Drug treatment of osteoporosis is based on the knowledge of mechanisms of bone turnover and the manipulation of the cellular components of bone turnover in terms of recruitment, activation and apoptosis of the cells involved. Based on their mechanisms of action, drugs used in the treatment of osteoporosis can be divided into those that inhibit bone turnover (bisphosphonates, SERMs, calcitonin), those that stimulate bone turnover (parathyroid hormone), and those with mixed effects (strontium ranelate). In this chapter we discuss the anti-fracture effects of some newer drugs together with innovative aspects of intake (monthly oral intake for ibandronate) or mechanisms of action (parathyroid hormone and strontium ranelate). Some new drugs that are being studied for their potential anti-fracture effects are listed.

摘要

骨质疏松症的药物治疗基于对骨转换机制的了解，以及从参与骨转换的细胞的募集、激活和凋亡方面对骨转换的细胞成分进行调控。根据其作用机制，用于治疗骨质疏松症的药物可分为抑制骨转换的药物（双膦酸盐、选择性雌激素受体调节剂、降钙素）、刺激骨转换的药物（甲状旁腺激素）以及具有混合作用的药物（雷奈酸锶）。在本章中，我们将讨论一些新型药物的抗骨折作用以及给药方式（伊班膦酸钠每月口服给药）或作用机制（甲状旁腺激素和雷奈酸锶）的创新之处。还列出了一些正在研究其潜在抗骨折作用的新型药物。